Clinical efficacy and safety of Cadonilimab in the treatment of advanced gynecological malignancies: a retrospective, real-world study
Abstract Background Cadonilimab, recognized as the most rapidly developed Chinese drug in the field of cervical cancer, received marketing approval in China in 2022. We conducted a study to investigate the safety and efficacy of Cadonilimab, combined with and without chemotherapy or bevacizumab trea...
Saved in:
| Main Authors: | Yisidan Huang, Yuting Zeng, Cui Zhang, Can Yang, Hanqun Zhang, Libo Li, Xiaoqing Luo, Yunchong Liu, Jiaying Bai, Fenghu Li, Yong Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14603-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical progress of cadonilimab in the treatment of malignant tumor
by: ZHANG Xiaoqing, et al.
Published: (2025-06-01) -
Advances and obstacles of T cell-based immunotherapy in gynecological malignancies
by: Xi Zhao, et al.
Published: (2025-07-01) -
The Influence of Gynecological Malignancies and Patient Characteristics on Fall Risk Perception
by: Jingjing Gong, et al.
Published: (2024-05-01) -
Case Report: Cadonilimab plus anlotinib with radiotherapy for lung adenocarcinoma with pancreatic metastasis in later-line therapy
by: Jianquan Yang, et al.
Published: (2025-07-01) -
Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study
by: Yilin Wang, et al.
Published: (2025-04-01)